《SoftServe：2024年生命科學領域人工智能應用價值分析報告：戰略整合與實施路徑（英文版）（16頁）.pdf》由會員分享，可在線閱讀，更多相關《SoftServe：2024年生命科學領域人工智能應用價值分析報告：戰略整合與實施路徑（英文版）（16頁）.pdf（16頁珍藏版）》請在三個皮匠報告上搜索。

1、WHERE IS GEN AIS VALUE HIDING IN LIFE SCIENCES?Insights from a 2024 commissioned global study conducted by Forrester Consulting on behalf of SoftServeBy:Steve LoSardoReportWhere Is Gen AIs Value Hiding In Life Sciences?2The life sciences industry is changing dramatically,with more companies using Ge

2、nerative AI(Gen AI).A 2024 commissioned global study conducted by Forrester Consulting on behalf of SoftServe details where Gen AI implementation currently stands in this sector,and where its heading.The 2024 study shows that life science companies are actively exploring AI solutions to transform th

3、eir business models and fulfill their mission to develop innovative treatments to enhance patient care.For this reason,they are seeking value in the following areas:SoftServes report explores first-hand insights from life science organizations on the state of Gen AI and perspectives for how to accel

4、erate the pace of adoption.Business strategy:More companies are shifting toward data-driven forecasting,with 57%prioritizing improving business strategy as a top Gen AI goal.Despite 85%expecting Gen AI to become more important in this area,32%express a need for help in refining their strategy roadma

5、p.HCP/patient engagement:55%of respondents want to improve healthcare provider(HCP)/patient engagement using Gen AI,with a notable shift from a product-centric to a customer-centric approach in the industry.Autonomous customer service,augmented customer support,and virtual assistants are key uses of

6、 Gen AI in engagement.Software development:53%consider improving software development a priority with Gen AI.Within the next 12-18 months,87%believe Gen AI will play an even bigger role in this field.Employee experience:A focus on reskilling and upskilling with Gen AI is clear,with 51%prioritizing e

7、nhancing employee experience.The study suggests a strong link between employee satisfaction,productivity,and Gen AI investment.Research and development(R&D):There is a growing confidence in Gen AIs potential to address current challenges in R&D like clinical trial operations,and repurposing existing

8、 drugs for new indications.Forty-two percent of survey participants plan to invest in Gen AI for R&D purposes.EXECUTIVE SUMMARYReportWhere Is Gen AIs Value Hiding In Life Sciences?3THE URGENT CALL FOR INNOVATIONSEEKING VALUELike many industries,the life sciences industry is facing significant extern

9、al headwinds in 2024,such as declining profitability and ROI,rising capital costs,and outdated therapeutic portfolios.Additionally,there is intense competition from generics and biosimilars,compounded by patent expirations.With mounting competition,the industry struggles to gain reimbursement from h

10、ealthcare payers and secure distribution channels.The increasing costs for research,development,and manufacturing put pressure on profitability.Meanwhile,companies need to keep up with the rapid pace of technological change,including advancements in AI,IoT,and digital health.All this while protectin

11、g sensitive patient data and ensuring compliance with data privacy.Facing those challenges,the industry is now keenly adopting Gen AI.Theres been a quick and eager move to kick off ambitious proof-of-concept projects.For instance,companies are exploring use cases that speed up drug discovery,make cl

12、inical trials more efficient,accelerate regulatory approvals,and quickly create highly personalized marketing materials.A 2024 commissioned global study conducted by Forrester Consulting on behalf of SoftServe reveals that life science companies know how powerful AI can be.As a result,theyre seeking

13、 value in the following areas.The most important Gen Al goals in life sciences todayImproving business strategy57%Improving customer engagement55%Improving employee experience51%Improving operational efficiency43%Improving research and development42%Improving risk management/regulation42%Improving s

14、ales30%Improving software development53%ReportWhere Is Gen AIs Value Hiding In Life Sciences?41:IMPROVE BUSINESS STRATEGYWith so much cost and competitive pressure facing the life sciences industry,more companies are looking to data-driven insights to guide their business strategies.The strategic us

15、e of data is changing how organizations prioritize R&D,handle regulatory compliance,form collaborations,and manage their talent.A successful business strategy should deliver the therapies patients need,as well as drive value creation,enhance market position,and ensure long-term sustainability.Yet,we

16、re seeing that smaller companies are somewhat hesitant to try Gen AI.Their conservatism stems from a belief that their current systems are good enough.Despite reservations,these companies are watching the big players closely and are ready to jump in once they see Gen AI working well elsewhere.This h

17、ighlights the importance of a well-rounded business strategy before adopting Gen AI.Fifty-seven percent of companies consider improving their business strategy as a top Gen AI goal,a figure higher than the industry average of 51%.Encouragingly,85%believe that Gen AI will take on a larger role within

18、 this area in the next 12-18 months.However,the study also revealed some concerns:32%acknowledged that they needed help refining their business strategy to keep up with Gen AI.This problem appears to be more prevalent in this sector than others.As companies strive to enhance their business strategie

19、s,some are leading the way in implementation.Under the visionary leadership of CEO Paul Hudson,Sanofi set the pace with a goal to be the first pharma company powered by AI at scale.The company has rolled out a comprehensive Gen AI platform that compiles and analyzes internal data.It allows for real-

20、time data interactions,offers detailed insights,and helps with scenario planning,making decision-making easier.The Forrester Consulting study offered interesting insights:ReportWhere Is Gen AIs Value Hiding In Life Sciences?52:IMPROVE HCP/PATIENT ENGAGEMENTThe wider HCP/patient engagement landscape

21、is changing,and companies need to adapt.The following trends clearly show this:There is significant potential for companies to use AI to engage with HCPs/patients.However,many companies find meeting the HCP requirements for relevant,differentiated content challenging.Reflecting these challenges,55%o

22、f respondents said improving customer engagement is their next big goal with Gen AI,slightly higher than the industry average of 53%.Also,70%plan to focus more on this goal in the next 12-18 months.Many applications focus on building a strong foundation for understanding customer insights,allowing c

23、ompanies to respond to real-time AI analysis.For instance,call notes are taken after conversations,and Gen AI can sift through this text,finding common issues.These notes and the AI insights can be shared across the company to improve how HCPs engage with patients and caregivers and the messages the

24、y use.A few other use cases that enhance engagement include:Autonomous HCP service Augmented patient support Virtual assistants and coaching on medical concept learning AI-powered contact centers and chatbots Sentiment analysis for personalizationDigital health:Digital health technologies like mobil

25、e apps,wearables,and telemedicine are making it easier for HCPs and patients to have personalized and convenient interactions.Data-driven insights:Using data analytics to understand what HCPs and patients prefer,how they behave,and what they need helps create more targeted and effective ways to enga

26、ge with them.ReportWhere Is Gen AIs Value Hiding In Life Sciences?6Augment,not replace:Gen AI in patients livesThe goal is not to replace human workers but to make certain daily activities easier.The study reveals that:Currently,a sizable number(57%)of companies are using Gen AI to automate service

27、tasks,with many others(30%)in the pilot stage.But in the next 12 to 18 months,companies will sharpen their focus on augmented support,while moving away from autonomous support.Companies favor launching new Gen AI initiatives to augment patient support(32%)rather than automate it(9%).Of the 87%alread

28、y using or piloting Gen AI for autonomous support,half dont plan to expand this use in the next 12-18 months.Meanwhile,of the 64%using or piloting Gen AI for augmented support,only a third dont plan to expand their use.The findings show a preference for a hybrid approach that combines AI with human

29、interaction.At Bayer,Gen AI is helping researchers access,identify,and correlate data.Now they can mine large troves of research data for possible connections and automate the time-intensive tasks of drafting clinical trial communications into different languages.Gen AI can enhance patient support s

30、ervices in the industry,for example,by analyzing patient data to provide personalized messages and recommendations,improving engagement and adherence.By anticipating patient needs based on data,Gen AI can proactively reach out with relevant information and support.Gen AI can send timely reminders an

31、d personalized messages to encourage medication adherence and improve patient outcomes.AI-powered virtual assistants can provide patients with instant answers to common questions,reducing the burden on human agents.For example,patients with Type 2 diabetes can use Gen AI to manage their chronic cond

32、itions.A virtual coach(VC)supports patients alongside HCPs,turning feelings of failure into motivation and simplifying the management of their disease.Virtual coach recommends a healthy dietVC predicts responses to treatmentVC drives awareness and facilitates adherenceVC suggests recipesVC encourage

33、s exerciseVC connected to glucose monitoringDigital twin(DT)predicts predispositionDT predicts response to treatmentAl chatbot delivers medical informationReportWhere Is Gen AIs Value Hiding In Life Sciences?73.IMPROVE SOFTWARE DEVELOPMENTImproving software development is currently the third top pri

34、ority for Gen AI,with 53%considering it important.Within the next 12-18 months,87%believe Gen AI will play an even bigger role in this field.The study highlights that the IT and software departments are experiencing the most significant benefits from Gen AI,with 62%of IT workers reporting significan

35、t value.This is notably higher than the average across all sectors(51%).Speeds up the delivery of value and insights Makes data insights more accessible to everyone Automates the creation of technical designs Integrates AI into diagnostic software Improves the synchronization and accuracy of hospita

36、l medical systemsGen AI improves software development for budget-conscious clientsSoftServe recently conducted research highlighting the impact of Gen AI on software development.Our findings show that while the results may be similar,Gen AI drastically speeds up the software development process,impr

37、oving efficiency.This is especially important for companies with strict budget constraints.Our study revealed that Gen AI:Gen Al goals in 12-18 monthsMore importantMuch more importantImproving software development42%45%Improving business strategy43%42%Improving operational efficiency42%40%Improving

38、research and development40%38%Improving sales40%38%Improving employee experience42%36%Improving risk management/regulation40%36%Improving customer engagement40%30%ReportWhere Is Gen AIs Value Hiding In Life Sciences?84:IMPROVE EMPLOYEE EXPERIENCERespondents realize they cant scale innovation and AI

39、without developing their employees skills.So,theres a big focus on re-skilling and up-skilling to ensure theres a strong emphasis internally.Looking ahead,the growing focus on improving employee experience and the potential of intelligent enterprise search suggest that life science companies will co

40、ntinue to invest in Gen AI solutions that enhance both employee engagement and access to critical information.See a strong link between employee satisfaction and overall productivity Are investing in technologies that make it easier for employees to access information and perform their jobs more eff

41、iciently Are ahead of other sectors in realizing the benefits of Gen AIThe study reveals that:These findings suggest that companies:Currently,51%say that enhancing employee experience is among their top goals,significantly higher than the industry average of 44%and above 41%in healthcare.A practical

42、 example of this is Merck,which is using MyGPT(comparable to ChatGPT)internally to enhance efficiency and productivity in a safe,secure,and compliant way within Mercks data infrastructure.New features include“bring your own documents.”Intelligent employee support is the most piloted use case for Gen

43、 AI,featuring tools like conversational search,summarization,data analysis,creativity,and content generation.Employee experience and HR are second only to IT in achieving a return on investment from their Gen AI projects.Today,46%report gaining“significant value”from these initiatives,outperforming

44、other sectors(41%).Over the next 12-18 months,use of Gen AI for improving employee experience is expected to grow for 77%of those surveyed.Intelligent enterprise search stands out as another high-potential application,with a quarter of companies currently testing it and another 25%using it with plan

45、s to expand in the next year.ReportWhere Is Gen AIs Value Hiding In Life Sciences?95:IMPROVE RESEARCH AND DEVELOPMENTPrecision medicine,an innovative approach to tailoring disease prevention and treatment that considers differences in peoples genes,environments,and lifestyles,holds great promise.How

46、ever,it faces challenges like data collection,costs,and privacy issues.Gen AI could be the answer,generating synthetic data to create a digital twin of a patient that maintains privacy,thereby advancing patient-centered healthcare.SoftServes partnership with NVIDIA in drug discovery is a strategic c

47、ollaboration focused on using AI and high-performance computing to accelerate the drug discovery process.SoftServe uses NVIDIAs BioNeMo platform,including its powerful GPUs and frameworks,to accelerate AI model training and inference in drug discovery.The impact of Gen AI on clinical trials is anoth

48、er area ripe with potential.For example,pharmaceutical companies face excessive costs to get a drug into clinical trials.Gathering the right trial participants is expensive and time-consuming.Since Gen AI can rapidly analyze vast quantities of structured and unstructured data,it can be used as a pow

49、erful study-team companion,which can share insights to help guide the best clinical trial participants and suggest effective interventions to improve the outcomes of clinical trials.Another example is where NLP and Gen AI are combined to identify existing drugs that could be used for new indications

50、.40%of respondents cited that using Gen AI to improve R&D will become more important over the next 12-18 months;38%said it is much more important.Over half of the surveyed individuals are either planning to invest in Gen AI or already testing it in pilot projects,with another 11%of respondents shari

51、ng that their department plans to expand use cases in the next 12-18 months.The study reveals that:40%1/2There is growing confidence in the technologys potential to address current R&D challenges.Highlighting a practical application,Bristol Myers Squibb has successfully discovered the first compound

52、 candidate for immunology and inflammation indications with a more efficient drug design and development process created by a Gen AI Precision Medicine Platform.Other promising use cases include:Disease prediction and prototyping Molecular design Clinical trial optimization Protein structure predict

53、ionReportWhere Is Gen AIs Value Hiding In Life Sciences?10Eighty-one percent of respondents in the Forrester Consulting study rated Gen AI based operational efficiency as becoming more important or much more important in the next 12 to 18 months.This is in line with companies we talk to that are fin

54、ding practical operational AI use cases that deliver measurable business impact:Clinical trials:Gen AI speeds up clinical trials by quickly finding patients,analyzing large datasets to spot trends and adverse events,and looking at risks to take early action.Medical literature review:Gen AI transform

55、s how we search and analyze medical information.It gets the nuances of medical language for better search results,summarizes research findings automatically,and pulls out important data for analysis.It also detects biases,analyzes citations to improve quality,builds knowledge graphs to see how conce

56、pts connect,and checks documents for legal and regulatory compliance.Regulatory compliance and medical affairs:Gen AI transforms regulatory compliance and medical affairs.It speeds up document review,improves risk assessment,simplifies managing data,reviews medical literature more efficiently,helps

57、with medical writing,and tailors patient engagement programs.OPERATIONAL EFFICIENCYReportWhere Is Gen AIs Value Hiding In Life Sciences?11Value harvesting from Gen Al by departmentModerate valueSignificant valueIT/software developmentResearch and developmentMarketing and salesCEO/office of the CEOEm

58、ployee experience/HRHCP/patient experience/serviceSupply chainLegal and complianceFinanceEcosystem managementOperations51%44%56%47%49%55%51%46%50%43%24%62%46%42%41%40%37%36%33%31%31%26%Wrapping up the survey,the focus shifted to exploring the value derived from Gen AI across various departments.Belo

59、w is a summary of the responses from the life sciences sector,detailing the extent to which each department has realized value to date.In priority order,value was achieved from:TODAYS VALUE PERSPECTIVEHCP/patient experience/service:Combined 92%have achieved moderate or significant value Marketing an

60、d sales:Combined 92%have achieved moderate or significant value R&D:Combined 91%have achieved moderate or significant value Employee experience:Combined 89%have achieved moderate or significant valueReportWhere Is Gen AIs Value Hiding In Life Sciences?12While 68%of life science companies have not ye

61、t realized their peak business value,half of these companies anticipate achieving this within the next 12 months.Data shows that life science companies face significant challenges and risks.The study reveals that:Operational value Companies worry theyre not fully using their Gen AI initiatives for o

62、perational efficiency.Forty-five percent express express great concern,compared to 37%in other industries.R&D Their second major concern is enhancing R&D,where 42%said they were concerned about their ability to execute Gen AI in R&D using their existing internal and external resources.Gen Al value r

63、ealization timelineMy organization doesnt expect to realize any business value0%4%My organization has yet to experience the most business value but expects this to occur in 24+months28%My organization has yet to experience the most business value but expects this to occur in 12 to 24 months36%My org

64、anization has yet to experience the most business value but expects this to occur in the next 12 months17%My organization is currently experiencing the highest level of business value15%My organization has already experienced the most business valueThe value that AI brings is not just limited to mak

65、ing better decisions,but also accelerating the decision-making processes.Early adopters like Lilly(using AI to automate patient narratives)and Siemens(using AI to address equipment issues)are already reaping the benefits.THE SEARCH FOR VALUESome companies we talk to see a significant gap between the

66、 expected potential and the value it currently provides.Given that most respondents said they are still preparing for the next version of the rollout after the production scale,we wanted to understand what the challenges are in doing so.The study conducted by Forrester Consulting shows a significant

67、 difference between what executives in all industries expect and whats happening.It found that although over 80%of those surveyed believe Gen AI will become more important in the next year,only about 32%feel they have fully tapped into Gen AIs potential in their organizations today.ReportWhere Is Ge

68、n AIs Value Hiding In Life Sciences?13Use cases for pilot and prototype development:Identifying use cases for pilots and developing and deploying prototypes is a significant challenge,with nearly half facing difficulties compared to 40%in other sectors.Security:The second and third most important ar

69、eas needing improvement are data security and the accuracy of language models,with 28%of people prioritizing these issues.Strategic roadmap:32%need help enhancing their strategic roadmaps to progress,the highest rate across all sectors.Data strategy:To mitigate these challenges to value,53%plan to a

70、ccelerate adoption by improving their data strategies,a higher figure than the 42%industry average.And 47%plan to increase their investment in Gen AI versus a larger percentage than for other industries.Focusing in on where help is needed with the life sciences Gen AI strategy,the key areas are as f

71、ollows:ReportWhere Is Gen AIs Value Hiding In Life Sciences?14EXTERNAL PARTNERS32%32%Many companies dont know how to make the most of their technology investments.The key is to collaborate with both internal and external partners.This collaboration could make it easier to handle complex data environ

72、ments,which is vital for data-driven areas like the life sciences industry.Most companies realize how important high-quality data is for creating strong AI systems.Ensuring data integrity leads to more accurate AI outputs,better decision-making,and ultimately,improved patient outcomes.By smartly usi

73、ng their technology investments,life science companies can improve their operations and speed up innovation,giving them an advantage in the highly competitive market.32%of those surveyed are teaming up with outside service providers for data governance.Additionally,32%need help fine-tuning their str

74、ategy roadmap to advance AI initiatives.THE SOFTSERVE DIFFERENCESelecting the right technology partner for implementation is important.You need a partner with proven ability,proven methodologies,and a deep understanding of its potential and limitations.One who understands your business,helps with or

75、ganizational readiness,and brings other specialties to the table as well.SoftServe is uniquely qualified to implement Gen AI and related technologies.We offer technical expertise,an industry understanding,and a large team of data scientists to bring the technology to life in your organization.Our en

76、gineers are backed by R&D,which keeps us at the forefront of new advancements.And we also have strong vendor relationships for Gen AI,including strategic partnerships with Amazon,Google Cloud,Microsoft,and NVIDIA.ReportWhere Is Gen AIs Value Hiding In Life Sciences?15METHODOLOGYIn this study,Forrest

77、er Consulting conducted a global online survey involving 777 decision-makers across various industries among which 52 worked in the life sciences industry who are engaged in technology purchasing related to Gen AI.The goal was to assess the effectiveness of their current adoption strategies.Particip

78、ants were questioned about their organizations Gen AI technology,infrastructure,skill development,governance strategies,and the value derived from their existing use of Gen AI.As a token of appreciation for their time,respondents received a small incentive.The study began in January and concluded in

79、 February 2024.Please note that percentages may not add up to 100 due to rounding.If you need a trusted AI consulting and technology partner to simplify where and how to make Gen AI a reality in your company,contact us today.CONTACT US5 RECOMMENDATIONS13245To get the most from Gen AI,life science co

80、mpanies need a solid strategy and a deep understanding of tech.Here are SoftServes five recommendations to get started:Focus on specific,high-value,low-risk use cases that deliver business value Align the organization around the incorporation of the new technology Clean and organize your data Integr

81、ate data sources before feeding them to the Gen AI model Select an experienced technology partnerNORTH AMERICAN HQ201 W.5th Street,Suite 1550 Austin,TX 78701+1 866 687 3588(USA)+1 647 948 7638(Canada)EUROPEAN HQ30 Cannon StreetLondon EC4 6XHUnited Kingdom+44 333 006 4341 ABOUT USSoftServe is a premi

82、er IT consulting and digital services provider.We expand the horizon of new technologies to solve todays complex business challenges and achieve meaningful outcomes for our clients.Our boundless curiosity drives us to explore and reimagine the art of the possible.Clients confidently rely on SoftServ

83、e to architect and execute mature and innovative capabilities,such as digital engineering,data and analytics,cloud,and AI/ML.Our global reputation is gained from more than 30 years of experience delivering superior digital solutions at exceptional speed by top-tier engineering talent to enterprise industries,including high tech,financial services,healthcare,life sciences,retail,energy,and manufacturing.Visit our website,blog,LinkedIn,Facebook,and X(Twitter)pages for more information.